VivoSeq
Oncology

Tumor Lysis Syndrome

6

Pipeline Programs↗

1

Active Trials↗

5

Companies Involved↗

Tumor Lysis Syndrome is an early-stage landscape with 6 programs across 5 companies. The most active players are Takeda, Alnylam Pharmaceuticals, Horizon Therapeutics Ireland DAC. 1 therapy is approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

88/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

1 program

Phase 3Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 3H

Horizon Therapeutics Ireland DAC

1 program

ApprovedSanofi logo

Sanofi

0 programs

PreclinicalMenarini logo

Menarini

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Protein / enzyme

4 of 6 classified programs — the dominant modality here.

33%ALL OTHERSSmall molecule233%

Protein / enzyme leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 100% of 6 pipeline programs.

Analysis

Trial Status

9

clinical trials

Completed7 · 78%
Active, not recruiting1 · 11%
Terminated1 · 11%

Clinical Trials

Trial Activity

9 trials

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 4·NCT04745910·10 enrolled
Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies
Completed·Menarini logoMenarini·Phase 3·NCT01724528·346 enrolled
Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome
Completed·Sanofi logoSanofi·Phase 4·NCT00563771·38 enrolled
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01200485·55 enrolled
Rasburicase in Patients at Risk for Tumor Lysis Syndrome
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00628628·82 enrolled
Rasburicase in Tumor Lysis Syndrome
Completed·Sanofi logoSanofi·Phase 4·NCT00302653·33 enrolled
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
Completed·Sanofi logoSanofi·Phase 3·NCT00230178·280 enrolled
Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy
Completed·Sanofi logoSanofi·Phase 4·NCT00230217·94 enrolled
Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults
Terminated·Menarini logoMenarini·Phase 1/2·NCT03605212·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)